Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego
CA
92121
United States
Tel: 858-453-7200
Fax: 858-453-7210
Website: http://www.arenapharm.com/
Email: invest@arenapharm.com
149 articles with Arena Pharmaceuticals, Inc.
-
Despite being represented in clinical research, no solutions have been found to circumvent the effects of Alopecia areata. However, there may be hope.
-
Pfizer Completes Acquisition of Arena Pharmaceuticals
3/11/2022
Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
-
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates
2/23/2022
Arena Pharmaceuticals, Inc. provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 17, 2022
2/17/2022
Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units.
-
Arena Pharmaceuticals to Release Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update on February 23
2/9/2022
Arena Pharmaceuticals, Inc. will release its fourth quarter and full-year 2021 financial results and provide a corporate update on Wednesday, February 23, 2022, after the close of the U.S. financial markets.
-
The San Diego-based immunology company is locating and developing molecules where the mechanism of action has either been proven or makes sense.
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 18, 2022
1/18/2022
Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted inducement restricted stock units to new employees.
-
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 21, 2021
12/21/2021
Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted to 16 new employees 28,659 inducement restricted stock units.
-
Pfizer to Acquire Arena Pharmaceuticals
12/13/2021
Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.
-
Arena Pharmaceuticals' share price nearly doubled in premarket trading after Pfizer announced it was acquiring the company and its diverse portfolio of developmental and clinical assets.
-
“I hope to thread the needle between pricing responsibly and achieving profitability," Jarrett said.
-
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod CULTIVATE Study A
11/19/2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has achieved target enrollment in Study A of the Phase 2/3 CULTIVATE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate to severe Crohn's disease (CD).
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 16, 2021
11/16/2021
Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted to 23 new employees inducement stock options to purchase an aggregate of 39,400 shares of its common stock and 18,760 inducement restricted stock units.
-
Arena Reports Third Quarter Financial Results and Key Program Updates
11/4/2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 21, 2021
10/21/2021
Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted inducement stock options and inducement restricted stock units to new employees.
-
Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4
10/14/2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2021 financial results and provide a corporate update on Thursday, November 4, 2021, after the close of the U.S. financial markets.
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 17, 2021
9/17/2021
Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted to 20 new employees inducement stock options to purchase an aggregate of 33,340 shares of its common stock and 15,655 inducement restricted stock units.
-
Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
9/2/2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced they will be hosting two virtual R&D Investor calls for analysts and investors focused on the Company’s etrasimod programs.
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 18, 2021
8/18/2021
Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units, and inducement restricted stock units to new employees.